| Título : |
Clinical efficacy of infliximab in moderate to severe ulcerative colitis in a latin american referral population |
| Tipo de documento : |
documento electrónico |
| Autores : |
Fabián Juliao Baños, ; Natalia Aristizábal Henao, ; Carlos Enrique Yepes Delgado, ; Julio Eduardo Zuleta Muñoz, |
| Fecha de publicación : |
2013 |
| Títulos uniformes : |
Digestion
|
| Idioma : |
Inglés (eng) |
| Palabras clave : |
Ulcerative colitis infliximab tumor necrosis factor α- Anti-tumor necrosis factor α |
| Resumen : |
Background: Previous research has shown that infliximab (IFX) is effective in the management of moderate to severe active ulcerative colitis (UC). Latin American studies are lacking. Aim: To evaluate the efficacy of IFX treatment (including corticosteroid withdrawal, complete mucosal healing, colectomy and hospitalization rates) in patients with moderate to severe UC. Methods: A retrospective and descriptive study was conducted on patients with UC in Medellín (Colombia). We included patients steroid dependent or refractory to conventional treatment. Results: Between October 2005 and July 2011, 28 patients with moderate to severe UC received IFX infusions; the median of the follow-up was 27.4 months (range: 1-69 months). Twenty-four patients (86%) had a short-term primary response, whilst 19 (68%) achieved initial clinical remission. After 1 year, 17 (71%) out of the 24 patients who had an initial response were also showing a sustained response, and 10 (42%) remained in clinical remission. At 6 months, complete mucosal healing was observed in 29% of patients and endoscopic improvement in 57%. Conclusions: This is the first study to evaluate the IFX use in patients with moderate to severe active UC in a Latin American population. We found that IFX therapy is effective for inducing clinical remission, and that most patients who had an initial response showed a long-term sustained response. |
| Mención de responsabilidad : |
Fabian Juliao, Juan Marquez, Natalia Aristizabal, Carlos Yepes, Julio Zuleta, Javier P Gisbert |
| Referencia : |
Digestion. 2013;88(4):222-8. |
| DOI (Digital Object Identifier) : |
10.1159/000355529 |
| PMID : |
24281150 |
| En línea : |
https://www.karger.com/Article/Abstract/355529 |
| Enlace permanente : |
https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3750 |
Clinical efficacy of infliximab in moderate to severe ulcerative colitis in a latin american referral population [documento electrónico] / Fabián Juliao Baños, ; Natalia Aristizábal Henao, ; Carlos Enrique Yepes Delgado, ; Julio Eduardo Zuleta Muñoz, . - 2013. Obra : DigestionIdioma : Inglés ( eng) | Palabras clave : |
Ulcerative colitis infliximab tumor necrosis factor α- Anti-tumor necrosis factor α |
| Resumen : |
Background: Previous research has shown that infliximab (IFX) is effective in the management of moderate to severe active ulcerative colitis (UC). Latin American studies are lacking. Aim: To evaluate the efficacy of IFX treatment (including corticosteroid withdrawal, complete mucosal healing, colectomy and hospitalization rates) in patients with moderate to severe UC. Methods: A retrospective and descriptive study was conducted on patients with UC in Medellín (Colombia). We included patients steroid dependent or refractory to conventional treatment. Results: Between October 2005 and July 2011, 28 patients with moderate to severe UC received IFX infusions; the median of the follow-up was 27.4 months (range: 1-69 months). Twenty-four patients (86%) had a short-term primary response, whilst 19 (68%) achieved initial clinical remission. After 1 year, 17 (71%) out of the 24 patients who had an initial response were also showing a sustained response, and 10 (42%) remained in clinical remission. At 6 months, complete mucosal healing was observed in 29% of patients and endoscopic improvement in 57%. Conclusions: This is the first study to evaluate the IFX use in patients with moderate to severe active UC in a Latin American population. We found that IFX therapy is effective for inducing clinical remission, and that most patients who had an initial response showed a long-term sustained response. |
| Mención de responsabilidad : |
Fabian Juliao, Juan Marquez, Natalia Aristizabal, Carlos Yepes, Julio Zuleta, Javier P Gisbert |
| Referencia : |
Digestion. 2013;88(4):222-8. |
| DOI (Digital Object Identifier) : |
10.1159/000355529 |
| PMID : |
24281150 |
| En línea : |
https://www.karger.com/Article/Abstract/355529 |
| Enlace permanente : |
https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3750 |
|  |
Inicio
Clasificado(s) por (Año de edición descendente) Refinar búsquedaClinical efficacy of infliximab in moderate to severe ulcerative colitis in a latin american referral population / Fabián Juliao Baños ; Natalia Aristizábal Henao ; Carlos Enrique Yepes Delgado ; Julio Eduardo Zuleta Muñoz
